BioPharma Resources

Drug Trial Radar · NCT03264664

Study of E7386 in Participants With Selected Advanced Neoplasms

An Open-Label, Multicenter, Phase 1 Study of E7386 in Subjects With Selected Advanced Neoplasms

Last checked: Nov 19, 2026Latest source record: Jun 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Jul 27, 2017

Primary completion

Mar 31, 2027

Study completion Mar 31, 2027

Sponsor

Lead sponsor
Eisai Inc.Eisai
Sponsor type
Industry
First posted
Aug 29, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will be conducted to assess the safety/tolerability profile of E7386 as a single agent administered orally in participants with selected advanced or recurrent neoplasms and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of E7386.

Conditions

  • Advanced Neoplasms

Interventions

  • E7386Drug

    Oral immediate release tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Dose-limiting Toxicities (DLTs)Time frame: Cycle 1 (28 days)
  2. Recommended Phase 2 Dose (RP2D)Time frame: Cycle 1 (28 days)
  3. Number of Participants with Treatment Emergent Adverse Events (TEAEs)Time frame: From the date of first dose of study drug up to 28 days after administration of study drug (up to approximately 6 years and 10 months)

Locations

10 sites in 2 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Comprehensive Caner

    Phoenix, Arizona

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California

  • California Liver Research Institute

    Pasadena, California

  • Mayo Clinic Comprehensive Cancer

    Jacksonville, Florida

  • Mayo Clinic Comprehensive Caner

    Rochester, Minnesota

  • UT Southwestern Medical Center

    Dallas, Texas

  • Imperial College Healthcare NHS Trust

    London, United Kingdom

  • The Beatson West of Scotland Cancer Centre

    Glasgow, Lanarkshire, United Kingdom

  • The Christie NHS Foundation Trust

    Manchester, Lancashire, United Kingdom

  • Royal Marsden Hospital NHS Foundation Trust

    Sutton, Surrey, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.